SHARE THIS WEBSITE

The CAPRISA 004 Tenofovir Gel Trial was conducted from 2007 to 2010 and included about 1000 women from Durban and Vulindlela, KwaZulu-Natal.
READ MORE

PARTNER INSTITUTIONS

National Institute for Communicable Diseases

CAPRISA is an official research institute of the University of KwaZulu-Natal and Columbia University.

CAPRISA was established in 2002 through a CIPRA grant from the NIH, as a multi-institutional collaboration, incorporated as an independent non-profit AIDS Research Organization.

CENTER FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.
READ MORE ABOUT CAPRISA

LATEST RESEARCH FINDINGS

Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women
Background HIV prevention trials are increasingly being conducted in sub-Saharan Africa. Women at risk for HIV are also at risk of pregnancy. To maximize safety, women agree to avoid pregnancy during trials, yet pregnancies occur. Using data from the HVTN 503/“Phambili” vaccine trial, we report pregnancy incidence during and after the vaccination period and identify factors, measured at screening, associated with incident pregnancy.

READ ENTIRE ARTICLE VIEW ALL ARTICLES

LATEST HAPPENINGS

CAPRISA's response to the FDA panel recommendation for daily Truvada as PrEP
CAPRISA Director, Professor Salim Abdool Karim welcomes the US Food and Drug Administration's (FDA) advisory panel's recommendation on 10 May 2012 that Truvada be made available as pre-exposure prophalaxis (PrEP). In response to the FDA's decision, Professor Abdool Karim said: "This is an historic moment in the fight to reverse the HIV epidemic, particularly in some of the hardest hit populations.

READ ENTIRE ARTICLE VIEW ALL ARTICLES

CAPRISA RESEARCH IN THE NEWS

Home